Four new drugs will change prostate cancer care

February 16, 2012

After a decade and a half of near stagnation, four new drugs could help make advanced prostate cancer a chronic illness instead of a terminal disease, a leading Colorado prostate cancer expert says.

"It's not just chemotherapy. The drugs have different and innovative methods of action. One is a bone protective agent; another's a more effective hormone agent; another is radiotherapy; and the final one is the first drug tested for ," says E. David Crawford, MD, investigator at the University of Colorado Cancer Center and head of urologic oncology at University of Colorado Hospital.

"Even without the addition of any more drugs, we may now have the tools that in combination will allow us to extend the survival prognosis of a patient long enough to make prostate cancer a disease a patient is more likely to die with than from," Crawford says.

Along with Thomas Flaig, MD, Crawford describes these advances in in a recent review for the journal Oncology.

First is the drug Denosumab, which Crawford says, "has three uses in protecting the bones of prostate cancer patients." It can prevent in patients with existing bone metastasis; it can prevent osteoporosis in patients whose calcium is depleted as a side-effect of hormone therapy; and (pending ) it has been shown to hold off the occurrence of bone metastasis for an average of four months in patients whose spiking PSA scores predict the likely onset of bone involvement.

Second is the drug Alpharadin, which is one of a novel and exciting class of "radiopharmaceuticals" – drugs that emit radiation and allow doctors to precisely deliver radiation to tumor sites. In the case of Alpharadin, it emits alpha rather than beta particles, which allows more precise tumor targeting of sites with less collateral damage to surrounding bone marrow.

Third, the drug Prostvac is the first "immunotherapy" drug used for the treatment of cancer. The drug acts like a vaccine, priming the immune system to recognize and thus fight against prostate cancer cells. In a phase II clinical trial of 125 patients, the drug extended the median survival time from 16.6 to 25.1 months.

Finally, the drug Abiraterone Acetate completely suppresses the body's ability to make testosterone, which many prostate cancers need to grow (as opposed to previous drugs, which hoped to out-compete testosterone with estrogen, or imperfectly controlled testosterone production).

Crawford notes that these drugs are being approved for use only after more established therapies have failed and hopes that in coming years science may accelerate the use of these drugs to first-line therapies.

E. David Crawford, MD, investigator at the University of Colorado Cancer Center

"Before we just had hormone therapy, then we got chemo, and each therapy we added packed on another couple months of survival. Now with these news drugs we're tacking on even more time. The light at the end of the tunnel is the hope that we'll turn this into a chronic disease and now we might have the tools that in some combination will do it," Crawford says.

Explore further: Denosumab delays development of prostate cancer bone metastasis

Related Stories

Denosumab delays development of prostate cancer bone metastasis

November 16, 2011
An international clinical trial has found that treatment with a drug that suppresses the normal breakdown of bone can delay the development of bone metastases in men with prostate cancer. The study, receiving Online First ...

Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival

January 12, 2012
Jefferson's Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind ...

Drug treatment extends lives of men with prostate cancer

May 26, 2011
(Medical Xpress) -- A drug recently approved by the Food & Drug Administration for the treatment of prostate cancer is proving to give some patients the gift of time.

More radionuclide therapy is better for prostate cancer patients

November 1, 2011
For prostate cancer patients with bone metastases, repeated administrations of radionuclide therapy with 188Re-HEDP are shown to improve overall survival rates and reduce pain, according to new research published in the November ...

First Phase III trial of an alpha-pharmaceutical

September 23, 2011
Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited. But now the first Phase III study of an alpha-pharmaceutical in these patients has shown that it can prolong ...

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

MyPhysorgID
not rated yet Feb 17, 2012
I am appalled, frankly, that an article of this nature and scope would ignore the revolutionary treatment Provenge for end stage prostate cancer. Intended for men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer, the treatment provides a 4.1-month median life extension benefit. Recent analyses presented at 2011 ASCO and 2012 GU, however, took into the account the crossovers from the placebo cohort that were given a frozen form of Provenge called Frovenge. With these patients removed from the cohort, the median life extension benefit for Provenge was found to range between 7.8 and 12.1 months. How a treatment such as Provenge escaped this author is beyond comprehension. There is nothing on the market or even close to market today that provides such a benefit to men as does Provenge.
ocyan
not rated yet Feb 17, 2012
Dr. Crawford, you mistook "Prostvac" for "Provenge". Provenge is an immunotherapy that has been approved by the FDA and is being used to treat patients with minimally symptomatic metastatic prostate cancer. "Prostvac" is still being tested in a phase-3 trial whose results will not be known for a few years.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.